trending Market Intelligence /marketintelligence/en/news-insights/trending/IOstm0sEUP426nqxEuJhjA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Sanofi secures rights to cancer biosimilar for Chinese market

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sanofi secures rights to cancer biosimilar for Chinese market

Sanofi is partnering with JHL Biotech Inc. to develop and commercialize biological therapeutics for the Chinese market.

Sanofi will invest US$80 million in the Taiwan-based biopharmaceutical company and pay a further US$21 million to secure rights to JHL's proposed biosimilar of Rituximab, a drug used to treat certain types of cancers.

JHL Biotech will be responsible for developing and registering the biosimilar while Sanofi will head commercialization in China.

In addition to sales royalties, JHL Biotech will also be eligible to receive up to US$236 million in milestone payments as a result of the deal.